Leeds microbubbles team prepares for start-up support from NELSA programme
A Leeds-based team will receive expert help in becoming ready for investment, from a new North of England Life Science Accelerator (NELSA) designed to turn ideas into businesses.
An expert panel from NELSA has selected eight business ideas, including Horizon: therapeutic microbubbles from the University, to benefit from mentors, coaching and workshops and help them on the next stage of their commercial journey.
Academic Fellow, Dr Sally Peyman, said: Horizon: therapeutic microbubbles provides world leading microfluidic technology to produce therapeutic microbubbles coated with a drug payload that can be used to deliver treatments to specific target sites in the body, such as a cancerous tumour. Once targeted, drug release from bubbles can be triggered by ultrasound, thus reducing off site toxicity and increasing local dosage.
The NELSA process so far has proven extremely useful in helping the Leeds microbubble consortium to think how best to take the technology from the lab and focus on understanding customer requirements to enable effective future development of the technology. We are excited to enter the next phase of the NELSA process to develop this opportunity further.
The NELSA initiative is anchored at Alderley Parks BioHub and was launched at the 2016 annual BioCap Conference.Posted in: University news